Objective To compare the clinical efficacy and safety of insulin degludec(IDeg)and insulin glargine(IGlar)in patients with type 2 diabetes mellitus(T2DM).Methods Totally 80 T2DM patients with poor plasma glucose control who were admitted to Shijiazhuang People's Hospital were randomized 1:1 to receive either IDeg(IDeg group,n=40)or IGlar(IGlar group,n=40).Patients were monitored by dynamic blood glucose meter at the first two weeks,and the follow-up was performed after two weeks(once a week for 12 weeks).The fasting plasma glucose(FPG),2-h postprandial plasma glucose(2-hPG),Hemoglobin A1c(HbA1c),insulin dose and several indicators reflecting glycemic variability were compared.Results A total of 75 patients completed the follow-up,including 39 cases of IDeg and 36 cases of IGlar.There was no statistically significant difference in age,body mass index(BMI),plasma glucose,HbA1c between groups.The standard deviation of FPG(FPG-SD),FPG coefficient of variation(FPG-CV)in IDeg group were significantly lower than those of IGlar group(P＜0.001).The time in range(TIR),mean blood glucose(MBG),standard deviation(SD),mean amplitude of glycemic excursion(MAGE),largest amplitude of glycemic excursion(LAGE)and mean of daily differences(MODD)were comparable between groups.At the end of follow-up,FPG and insulin dose in IDeg group were significantly lower than those in IGlar group(P＜0.05),while HbA1c and the decrease amount of HbA1c in the two groups was roughly the same.The risk incidence of hypoglycemia and nocturnal hypoglycemia was significantly lower in IDeg group than that in IGlar group(P＜0.05).Conclusion IDeg has the same clinical efficacy as IGlar,with less variability in plasma glucose,lower risk of hypoglycemia,and higher safety.
NETL
NSTL
万方数据
